NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jun 23 04:00PM ET
1.88
Dollar change
+0.02
Percentage change
1.08
%
IndexRUT P/E- EPS (ttm)-2.16 Insider Own54.53% Shs Outstand50.10M Perf Week1.62%
Market Cap94.26M Forward P/E- EPS next Y-0.60 Insider Trans-0.13% Shs Float22.80M Perf Month-1.05%
Enterprise Value-41.24M PEG- EPS next Q-0.14 Inst Own34.42% Short Float7.73% Perf Quarter11.90%
Income-106.50M P/S- EPS this Y80.67% Inst Trans-2.63% Short Ratio6.81 Perf Half Y-1.05%
Sales0.00M P/B0.62 EPS next Y-4.31% ROA-43.20% Short Interest1.76M Perf YTD-9.18%
Book/sh3.01 P/C0.59 EPS next 5Y38.88% ROE-54.64% 52W High15.25 -87.67% Perf Year-85.31%
Cash/sh3.18 P/FCF- EPS past 3/5Y4.05% -166.47% ROIC-62.15% 52W Low1.34 40.30% Perf 3Y-80.23%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility1.28% 1.95% Perf 5Y-
Dividend TTM- EV/Sales- EPS Y/Y TTM34.55% Oper. Margin- ATR (14)0.08 Perf 10Y-
Dividend Ex-Date- Quick Ratio25.32 Sales Y/Y TTM- Profit Margin- RSI (14)48.22 Recom3.00
Dividend Gr. 3/5Y- - Current Ratio25.32 EPS Q/Q87.45% SMA20-1.44% Beta0.74 Target Price2.00
Payout- Debt/Eq0.16 Sales Q/Q- SMA500.51% Rel Volume0.58 Prev Close1.86
Employees14 LT Debt/Eq0.14 EarningsMay 08 BMO SMA2002.05% Avg Volume259.12K Price1.88
IPOApr 29, 2022 Option/ShortNo / Yes EPS/Sales Surpr.67.12% - Trades Volume149,251 Change1.08%
Date Action Analyst Rating Change Price Target Change
Jul-09-24Downgrade Stifel Buy → Hold $34 → $3
Jul-09-24Downgrade Leerink Partners Outperform → Market Perform $28 → $2
Jul-09-24Downgrade H.C. Wainwright Buy → Neutral $28 → $2
Jul-08-24Downgrade JP Morgan Overweight → Neutral $24 → $5
Jul-08-24Downgrade Guggenheim Buy → Neutral
Dec-13-23Initiated H.C. Wainwright Buy $28
May-08-25 07:00AM
Mar-28-25 05:00PM
Nov-07-24 08:00AM
Oct-14-24 12:00PM
Aug-08-24 07:20PM
11:53AM Loading…
Aug-01-24 11:53AM
Jul-31-24 04:00PM
Jul-29-24 09:35AM
Jul-11-24 09:35AM
Jul-09-24 10:19AM
Jul-08-24 12:36PM
12:17PM
08:42AM
08:16AM
07:30AM
02:15AM Loading…
May-23-24 02:15AM
May-10-24 02:26PM
May-09-24 11:55PM
04:05PM
Apr-14-24 12:52PM
Apr-06-24 01:33AM
Mar-21-24 02:32AM
Mar-20-24 09:53PM
04:00PM
Mar-08-24 11:55PM
Feb-22-24 11:27PM
Feb-05-24 04:05PM
Jan-18-24 07:00AM
Jan-08-24 07:00AM
Jan-03-24 06:28PM
01:01PM Loading…
Dec-19-23 01:01PM
Dec-05-23 09:48PM
Nov-30-23 09:55AM
Nov-21-23 11:03AM
Nov-14-23 12:00PM
09:55AM
Nov-09-23 04:05PM
Nov-01-23 04:48PM
Sep-26-23 04:01PM
Sep-25-23 07:00AM
Sep-19-23 08:05PM
04:09PM
Aug-24-23 10:40AM
Aug-14-23 05:08PM
07:00AM
Jun-07-23 09:55AM
May-22-23 09:55AM
May-12-23 04:05PM
May-09-23 07:00AM
Apr-25-23 06:45AM
HilleVax, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel vaccines. Its pipeline includes Norovirus and HIL-214. The company was founded by Maurice Hilleman and Tadataka Yamada on March 25, 2020 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HERSHBERG ROBERTSee RemarksFeb 04 '25Sale1.8914,63427,6581,113,399Feb 12 04:05 PM
HERSHBERG ROBERTSee RemarksFeb 11 '25Sale1.7611,90121,0031,101,498Feb 12 04:05 PM
Maltbie ShaneChief Financial OfficerFeb 11 '25Sale1.764,3457,65979,887Feb 12 04:05 PM
Maltbie ShaneChief Financial OfficerFeb 04 '25Sale1.893,9467,45884,232Feb 12 04:05 PM